NCT06077422View on ClinicalTrials.gov

Exparel vs. Marcaine ESP Block for Post-cardiac Surgical Pain

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

January 11, 2024

Primary Completion Date

January 11, 2025

Study Completion Date

April 5, 2025

Conditions
Pain, PostoperativeOpioid UsePerioperative ComplicationHeart Diseases
Interventions
DRUG

bupivacaine liposome injectable suspension

Bupivacaine liposome injectable suspension (Exparel) will be administered by ultrasound-guided ESP block, unilaterally if thoracotomy on ipsilateral side, bilaterally if median sternotomy.

DRUG

Bupivacaine Hydrochloride

Bupivacaine HCl (Marcaine) will be administered by ultrasound-guided ESP block, unilaterally if thoracotomy on ipsilateral side, bilaterally if median sternotomy.

Trial Locations (1)

08903

RECRUITING

Rutgers RWJMS, New Brunswick

Sponsors
All Listed Sponsors
collaborator

Pacira Pharmaceuticals, Inc

INDUSTRY

lead

Rutgers, The State University of New Jersey

OTHER